Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

RK Ramanathan; DD von Hoff; Ferry Eskens; G Blumenschein; D Richards; I Genvresse; S Reschke; C Granvil; A Skubala; C Pena; K Mross

doi:10.1007/s11523-020-00714-0

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

RK Ramanathan, DD von Hoff, Ferry Eskens, G Blumenschein, D Richards, I Genvresse, S Reschke, C Granvil, A Skubala, C Pena, K Mross

Medical Oncology

Research output: Contribution to journal › Article › Academic

33 Citations (Scopus)

Original language	English
Pages (from-to)	163-174
Number of pages	12
Journal	Targeted Oncology
Volume	15
Issue number	2
DOIs	https://doi.org/10.1007/s11523-020-00714-0
Publication status	Published - 2020

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11523-020-00714-0

Cite this

Ramanathan, RK., von Hoff, DD., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Pena, C., & Mross, K. (2020). Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Targeted Oncology, 15(2), 163-174. https://doi.org/10.1007/s11523-020-00714-0

@article{43a727cf8f054b548524de701a640591,

title = "Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer",

author = "RK Ramanathan and {von Hoff}, DD and Ferry Eskens and G Blumenschein and D Richards and I Genvresse and S Reschke and C Granvil and A Skubala and C Pena and K Mross",

year = "2020",

doi = "10.1007/s11523-020-00714-0",

language = "English",

volume = "15",

pages = "163--174",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "2",

}

Ramanathan, RK, von Hoff, DD, Eskens, F, Blumenschein, G, Richards, D, Genvresse, I, Reschke, S, Granvil, C, Skubala, A, Pena, C & Mross, K 2020, 'Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer', Targeted Oncology, vol. 15, no. 2, pp. 163-174. https://doi.org/10.1007/s11523-020-00714-0

TY - JOUR

T1 - Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

AU - Ramanathan, RK

AU - von Hoff, DD

AU - Eskens, Ferry

AU - Blumenschein, G

AU - Richards, D

AU - Genvresse, I

AU - Reschke, S

AU - Granvil, C

AU - Skubala, A

AU - Pena, C

AU - Mross, K

PY - 2020

Y1 - 2020

U2 - 10.1007/s11523-020-00714-0

DO - 10.1007/s11523-020-00714-0

M3 - Article

C2 - 32314268

SN - 1776-2596

VL - 15

SP - 163

EP - 174

JO - Targeted Oncology

JF - Targeted Oncology

IS - 2

ER -